Skip to main content
SpringerLink
Log in

Therapie

  • Chapter
HIV und AIDS

  • 33 Accesses

Zusammenfassung

Studienteilnehmer der Multicenter Aids Cohort Study (MACS) wurden im Mittel über 10,6 Jahre beobachtet. Keiner der Studienteilnehmer bekam eine antiretrovirale Therapie zum Zeitpunkt der Studienaufnahme oder zum Zeitpunkt des Follow-up-Besuches nach 6 Monaten. Nur 41% der Patienten erhielten eine antiretrovirale Therapie im weiteren Verlauf der Beobachtung. Die Viruslast lag zu Beginn der Studie bei den Teilnehmern zwischen <500 und 294.200 HIV-RNA-Kopien/ml. Hinsichtlich der Viruslast und der CD4-Zellzahl wurden die Patienten in verschiedene Gruppen unterteilt. Dabei zeigt sich ein deutlicher Vorteil für die Patienten mit initial niedriger Viruslast.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Mellors J.W., Rinaldo Jr. C.R., Gupta P. et al.: Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma. Science 272: 1167–1170, 1996

    Article  PubMed  CAS  Google Scholar 

  2. Bauer G. ICA Vancouver: # 4258 (1996)

    Google Scholar 

  3. Bussel JB. Vox Sanguinis 52: 206–211 (1987)

    Article  PubMed  CAS  Google Scholar 

  4. Brunkhorst U, Stürner M, Willers H, Deicher H, Schedel I. Infection 18: 28–32 (1990)

    Article  Google Scholar 

  5. Kiehl MG, Stoll R, Domschke W. Immun Infekt 22: 53–55 (1994)

    PubMed  CAS  Google Scholar 

  6. Kiehl MG, Stoll R, Broder M, Mueller C, Foerster EC, Domschke W. Arch Int Med 156: 2545–2550 (1996)

    Article  CAS  Google Scholar 

  7. Rechtmann DJ. Use of Intravenous Immune Globulin in Adults with HIV Disease, in: Lee ML, Strand V (Hrsg.), Intravenous Immunoglobulins in clinical practise: 167–174. Dekker 1997

    Google Scholar 

  8. Rockstroh JK. Einsatz von Immunglobulinen bei HIV-infizierten Patienten, in: Jäger H (Hrsg.), AIDS: 269–271. MI 2000

    Google Scholar 

  9. Rubinstein A. Die gelben Hefte XXXI: 109–117 (1991)

    Google Scholar 

  10. Sanwo M, Nwadiuko, Beau G. J Allergy Clin Immunol 98:1112–1115 (1996)

    Article  PubMed  CAS  Google Scholar 

  11. Saint-Marc T, Berra N, Perraud P, Livrozet JM, Fournier F, Touraine JL. ICA Yokohama: # PB0330 (1994)

    Google Scholar 

  12. Saint-Marc T, Touraine JL, Berra N. Lancet 340: 1347 (1992)

    Article  PubMed  CAS  Google Scholar 

  13. De Simone C, Tzantzoglou S, Santini G, Vullo V, Orio F, Leuter C, Jirillo E, Delia S. Immunopharmacology and Immunotoxicology, 13:447–459 (1991)

    Article  PubMed  Google Scholar 

  14. Schrappe-Bächer M et al. Vox Sang 59 (Suppl 1): 3–14 (1990)

    Article  PubMed  Google Scholar 

  15. Williams PE, Thompson C, Yap PL, Brettle RP. Vox Sang, 60:126–127 (1991)

    Article  PubMed  CAS  Google Scholar 

  16. Mellors J.W., Rinaldo Jr. C.R., Gupta P. et al.: Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma. Science 272: 1167–1170, 1996

    Article  PubMed  CAS  Google Scholar 

  17. Beichert M., Buchholz B., Weigel M., Martini M., Breitkreutz R., Melchert F. (1999) Die materno-fetale HIV-Transmission, kein Problem mehr im Zeitalter von HAART? In: Mit AIDS leben, Jäger (Hrsg.) ecomed Verlag 1999

    Google Scholar 

  18. Beichert M., Buchholz B., Melchert F. Postexpositionsprophylaxe Notfall-Set; Sind wir für den Notfall gerüstet? Eur J Med Res (1999) 4(Suppl 1):F1143

    Google Scholar 

  19. Blanche S, Tardieu M, Rustin P, Slama A et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999 Sep 25; 354(9184):1084–9

    Article  PubMed  CAS  Google Scholar 

  20. Brockmeyer N. (1999) German-Austrian Guidelines for HIV-therapy during pregnancy-status: May/June 1998 — common statement of the Deutsche AIDS-Gesellschaft (DAIG) and the Österreichische AIDS-Gesellschaft (OAG). Eur J Med Res. 1999 Jan 26;4(1):35–42

    PubMed  CAS  Google Scholar 

  21. Buchholz B., Beichert M., Ramasubu K., Messen K. H., Böhler T. (1998) Reduction of vertical human immunodeficiency virus (HIV) transmission and medical follow-up of HIV-exposed children. Pädiatr. Grenzgeb., 1998, Vol. 37, pp. 133–149

    Google Scholar 

  22. Connor EM., Sperling RS., Gelber R., Kiselev P., Scott G., O’Sullivan MJ., Van Dyke R., Bey M., Shearer W., Jacobson RL. et al. (1994) Reduction of maternal-infant transmission of human immunodeficiency virus type-1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994 Nov 3; 331(18):1173–80

    Article  PubMed  CAS  Google Scholar 

  23. Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O Donnell K, Mofenson L, Gortmaker SL, Shapiro DE, Scott G, Jimenez E, Moore EC, Diaz C, Flynn PM, Cunningham B, Oleske J (1999) Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999 Jan 13; 281 (2):151–7

    Article  PubMed  CAS  Google Scholar 

  24. Deutsch-Österreichische Empfehlungen zur PEP (1998) Dtsch med Wschr 123 (1998), S 4–16

    Google Scholar 

  25. Dunn DT, Newell ML, Ades AE, Peckham CS (1992) Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet (1992); 340:585–8

    Article  PubMed  CAS  Google Scholar 

  26. Guay LA., Musoke P, Fleming T, Bagenda D et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial Lancet 1999 Sep 4; 354(9181):795–802

    CAS  Google Scholar 

  27. Landesman, SH., Kalish LA., Burns DN., Minkhoff H., Fox HE., Zorrilla C, Garcia P., Fowler MG., Mofenson L., Tuomala R. (1996) Obstetrical Factors And The Transmission Of Human Immunodeficiency Virus Type-1 From Mother To Child. N Engl J Med 1996 Jun 20; 334 (25): 1617–23

    Article  PubMed  CAS  Google Scholar 

  28. Lorenzi P., Spicher VM., Laubereau B., Hirschel B., Kind C., Rudin C., Irion O., Kaiser L. (1998) Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998 Dec 24; 12 (18):F241–7

    Article  PubMed  CAS  Google Scholar 

  29. Mandelbrod L., Le Chenadec J., Berrebi A., Bongain A., Benifla JL., Delfraissy JF., Blanche S., Mayaux MJ (1998) Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998 Jul 1; 280 (1): 55–60

    Article  Google Scholar 

  30. Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States 24.01.2001

    Google Scholar 

  31. Schaefer A., Friese K., Lauper U., Hebbisch G., Buchholz B., Diehm C., Grosch-Wörner I. (1998) Influence of cesarean section before parturition and antiretroviral prophylaxis on the materno-fetal transmission of HIV. 12th World AIDS Conference Geneva June 28.6.–3.7. 1998; Abstract 12466

    Google Scholar 

  32. Schäfer APA., Koch MA., Grosch-Wörner I. (1994) Wehen, Geburtsmodus und maternofetale Transmission von HIV. Geburtsh. Frauenheilk. 1994; 54: 617–622

    Article  Google Scholar 

  33. The International Perinatal HIV Group (1999) The Mode of Delivery and the Risk of Vertical Transmission of Human Immunodeficiency Virus Type 1; A Meta-Analysis of 15 Prospective Cohort Studies N Engl J Med 1999; 340:977–87

    Article  Google Scholar 

  34. Cardo DM et al. A case-Control Study of HIV Serokonversion in Health Care Workers after Percutaneous Exposure. New Engl J Med: 1485 (1997)

    Google Scholar 

  35. CDC Public Health Guidelines for the Mangement of Health-Care Worker Exposures to HIV and Recommendations for Postexposure Prophylaxis. MMWR 47: RR-7 (1998)

    Google Scholar 

  36. CDC. Serious Adverse Events Attributed to Nevirapine Regimes for Postexposure Prophylaxis after HIV Exposures-Worldwide, 1997–2000. MMWR 49: 1153–1156 (2001)

    Google Scholar 

  37. Henderson DK. Postexposure Chemoprophylaxis for Occupational Exposures to the Immunodeficiency Virus. JAMA: 931 (1999)

    Google Scholar 

  38. Jarke J. AIDS am Arbeitsplatz: Berufskrankheit HIV/AIDS, in: Jäger H (Hrsg.). AIDS. MI 2000

    Google Scholar 

  39. Petzoldt D, Hartmann M. Neue Möglichkeiten der medikamentösen Prophylaxe der beruflichen HIV-Infektion. Hautarzt 48: 295 (1997)

    Article  PubMed  CAS  Google Scholar 

  40. Barner A, Myers M, Nevirapine and Rashes. Lancet 351: 1133 (1998)

    Article  PubMed  CAS  Google Scholar 

  41. Bellmann PC. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitor has failed. AIDS 12: 1333–1340 (1998)

    Article  Google Scholar 

  42. Calista D, Boschini A. Cutaneous side effects induced by indinavir. Eur J Dermatol 10: 292–296 (2000)

    PubMed  CAS  Google Scholar 

  43. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 356: 1423–1430 (2000)

    Article  PubMed  CAS  Google Scholar 

  44. Deeks SG. Clinical Use of Efavirenz, Paris, unveröffentlicht (1999)

    Google Scholar 

  45. Freimuth WW. Delavirdine Mesylate, a potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitor. Antiviral Chemotherapy 4:279–290 (1996)

    Google Scholar 

  46. Brinkmann K, Smeitink JA, Romijn JA et al. Mitochondrial toxicity induced by nucleosid-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354: 1112–1115 (1999)

    Article  Google Scholar 

  47. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis and prediction of HIV protease inhibitor (PI)-induced lipodystrophy and impaired glucose tolerance. 6th Conference on Retroviruses and Opportunistic Infections, Chicago: #641 (1999)

    Google Scholar 

  48. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. “Buffalo hump” in men with HIV-1 infection. Lancet 351: 867–870 (1998)

    Article  PubMed  CAS  Google Scholar 

  49. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351: 871–875 (1998)

    Article  PubMed  CAS  Google Scholar 

  50. Boucher, C.A.B. und Larder, B.A., Viral variation and therapeutic strategies in HIV-infection, (1994), ISBN 1–89918–00–4

    Google Scholar 

  51. Iversen, A.K. et al., J. Virol. 70: 1086–1090

    Google Scholar 

  52. Larder, B. A., J. Gen. Virol. 75: 951–957 (1994)

    Article  PubMed  CAS  Google Scholar 

  53. Larder, B. A. et. al., Science 269: 696–699 (1995)

    Article  PubMed  CAS  Google Scholar 

  54. Loveday, C. et al., Lancet 345: 820–824 (1995)

    Article  PubMed  CAS  Google Scholar 

  55. Richman, D.D., Antimicrob. Agents Chemoth. 37:1207–1213 (1993)

    CAS  Google Scholar 

  56. Stuyer, L. et al., Int. Antiviral News 5: 38–40 (1997)

    Google Scholar 

  57. Stuyer, L. et al., Antimicrob. Agents Chemoth. 41: 284–291 (1997)

    Google Scholar 

  58. Tisdale, N. et al., PNAS 90: 5653–5656 (1993)

    Article  PubMed  CAS  Google Scholar 

  59. Hirsch MS et al. JAMA 283(18): 2417–2426 (2000)

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    HIV-Arbeitskreis Südwest

    Deutsche AIDS-Hilfe e.V.

    Editor information

    Editors and Affiliations

      Rights and permissions

      Reprints and permissions

      Copyright information

      © 2001 Springer-Verlag Berlin Heidelberg

      About this chapter

      Cite this chapter

      HIV-Arbeitskreis Südwest., Deutsche AIDS-Hilfe e.V.. (2001). Therapie. In: HIV und AIDS. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-97898-2_3

      Download citation

      • DOI: https://doi.org/10.1007/978-3-642-97898-2_3

      • Publisher Name: Springer, Berlin, Heidelberg

      • Print ISBN: 978-3-540-41642-5

      • Online ISBN: 978-3-642-97898-2

      • eBook Packages: Springer Book Archive

      Publish with us

      Policies and ethics

      Search

      Navigation